<DOC>
	<DOCNO>NCT01510431</DOCNO>
	<brief_summary>Protocol 620 provide PROCHYMAL ( R ) adult human mesenchymal cell specifically choose Crohn 's disease patient participate center typically already demonstrate good response another PROCHYMAL study , eligible PROCHYMAL study , view investigator , would benefit significantly Crohn 's therapy would benefit use PROCHYMAL . The study placebo-controlled randomize .</brief_summary>
	<brief_title>Safety Treatment Outcome Study PROCHYMALÂ® ( Remestemcel-L ) Intravenous Infusion Subjects With Treatment-resistant Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>currently active moderatetosevere Crohn 's disease exhaust standardofcare option age 18 70 inclusive body weight 30 150 kg adequate renal function risk TB activation reactivation biologic therapy Crohn 's within last 8 week confirm adverse reaction prior PROCHYMAL study participation alcohol substance abuse , current within past 6 month active HIV hepatitis B C infection surgery trauma 6 week allergy bovine porcine product elevate serum liver enzymes elevate serum bilirubin active malignancy within 5 year ( resect skin cancer ) bacteremia serious bacterial fungal infection within 3 month colonic dysplasia unstable arrhythmia serious heart condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>